Oncology nurse pride How Have Your Family Experiences With Cancer Impacted Your Decision to Become an Oncology Nurse? June 09, 2017
Genetics & genomics The Story of Henrietta Lacks Sheds Light on Ethical Considerations in Genetic Testing April 28, 2017
Topic Combination therapy U.S. Food and Drug Administration (FDA) FDA Approves Dabrafenib and Trametinib Combination for Metastatic NSCLC with BRAF V600E Mutation On June 22, 2017, the U.S. Food and Drug Administration granted (FDA) regular approvals to dabrafenib and trametinib (Taflinar® and Mekinist®, Novartis Pharmaceuticals Inc.) administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. June 23, 2017 Melanoma Combination Treatment Improves Survival for Advanced Melanoma A combination of nivolumab and ipilimumab improved overall survival when compared to either drug alone, according to results from a recent study reported at the American Association for Cancer Research 2017 annual meeting. June 21, 2017 ASCO Annual Meeting Chemotherapy Plus Radiotherapy Not Superior to Radiotherapy Alone in Improving Survival for Patients With High-Risk Endometrial Cancer Women with high-risk endometrial cancer (EC) are at an increased risk of metastasis and death. The randomized, intergroup PORTEC-3 study assessed the benefit of adjuvant chemotherapy during and after radiotherapy (RT) versus pelvic RT alone in this patient population. The researchers presented the study at the ASCO Annual Meeting. June 02, 2017 Clinical practice The Challenge of Caring for Multiple Patients With Cancer As more new treatments enter practice—like immunotherapy, targeted therapy, and combination therapies—oncology nurses are required to be experts in every treatment they administer. They need to constantly walk a tightrope, balancing multiple medications for one patient then quickly moving to the next patient on a completely different treatment protocol. May 17, 2017 Multiple myeloma Bortezomib May Improve Outcomes in Multiple Myeloma Adding bortezomib to combination therapy with lenalidomide and dexamethasone may improve progression-free and overall survival in patients with newly diagnosed multiple myeloma. The study findings were published in Lancet. April 12, 2017 Cancer treatments Combination Therapy Shows Promise for Chronic Myeloid Leukemia According to the results of a new study published in Science Translational Medicine, a combination regimen consisting of a BCR-ABL tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor may one day result in a cure for chronic myeloid leukemia. January 03, 2017 Cancer treatments Radiation Plus Chemotherapy Improves Survival From Low-Grade Gliomas A new study has shown that patients with grade 2 gliomas who are treated with radiation therapy plus a combination of chemotherapy have better survival than patients treated with radiation alone. The findings were published in the New England Journal of Medicine. June 01, 2016 Combination therapy FDA Approves Carfilzomib in Combination With Lenalidomide and Dexamethasone for Treatment of Relapsed Multiple Myeloma On July 24, 2015, the U.S. Food and Drug Administration approved carfilzomib (Kyprolis, Onyx Pharmaceuticals, Inc., an Amgen subsidiary) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. July 24, 2015 Combination therapy FDA Approves Combination of Mekinist and Tafinlar for Advanced Melanoma The U.S. Food and Drug Administration (FDA) granted accelerated approval to trametinib (Mekinist tablets, GlaxoSmithKline, LLC) and dabrafenib (Tafinlar capsules, GlaxoSmithKline, LLC) for use in combination in the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test. January 10, 2014 Trending Topics Safety Standards Research Treatments ONS Congress Clinical practice Immunotherapy U.S. Food and Drug Administration (FDA) Cancer research Nursing education View All Topics
U.S. Food and Drug Administration (FDA) FDA Approves Dabrafenib and Trametinib Combination for Metastatic NSCLC with BRAF V600E Mutation On June 22, 2017, the U.S. Food and Drug Administration granted (FDA) regular approvals to dabrafenib and trametinib (Taflinar® and Mekinist®, Novartis Pharmaceuticals Inc.) administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. June 23, 2017
Melanoma Combination Treatment Improves Survival for Advanced Melanoma A combination of nivolumab and ipilimumab improved overall survival when compared to either drug alone, according to results from a recent study reported at the American Association for Cancer Research 2017 annual meeting. June 21, 2017
ASCO Annual Meeting Chemotherapy Plus Radiotherapy Not Superior to Radiotherapy Alone in Improving Survival for Patients With High-Risk Endometrial Cancer Women with high-risk endometrial cancer (EC) are at an increased risk of metastasis and death. The randomized, intergroup PORTEC-3 study assessed the benefit of adjuvant chemotherapy during and after radiotherapy (RT) versus pelvic RT alone in this patient population. The researchers presented the study at the ASCO Annual Meeting. June 02, 2017
Clinical practice The Challenge of Caring for Multiple Patients With Cancer As more new treatments enter practice—like immunotherapy, targeted therapy, and combination therapies—oncology nurses are required to be experts in every treatment they administer. They need to constantly walk a tightrope, balancing multiple medications for one patient then quickly moving to the next patient on a completely different treatment protocol. May 17, 2017
Multiple myeloma Bortezomib May Improve Outcomes in Multiple Myeloma Adding bortezomib to combination therapy with lenalidomide and dexamethasone may improve progression-free and overall survival in patients with newly diagnosed multiple myeloma. The study findings were published in Lancet. April 12, 2017
Cancer treatments Combination Therapy Shows Promise for Chronic Myeloid Leukemia According to the results of a new study published in Science Translational Medicine, a combination regimen consisting of a BCR-ABL tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor may one day result in a cure for chronic myeloid leukemia. January 03, 2017
Cancer treatments Radiation Plus Chemotherapy Improves Survival From Low-Grade Gliomas A new study has shown that patients with grade 2 gliomas who are treated with radiation therapy plus a combination of chemotherapy have better survival than patients treated with radiation alone. The findings were published in the New England Journal of Medicine. June 01, 2016
Combination therapy FDA Approves Carfilzomib in Combination With Lenalidomide and Dexamethasone for Treatment of Relapsed Multiple Myeloma On July 24, 2015, the U.S. Food and Drug Administration approved carfilzomib (Kyprolis, Onyx Pharmaceuticals, Inc., an Amgen subsidiary) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. July 24, 2015
Combination therapy FDA Approves Combination of Mekinist and Tafinlar for Advanced Melanoma The U.S. Food and Drug Administration (FDA) granted accelerated approval to trametinib (Mekinist tablets, GlaxoSmithKline, LLC) and dabrafenib (Tafinlar capsules, GlaxoSmithKline, LLC) for use in combination in the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test. January 10, 2014
